RxDoctor Payments Data

Jennifer Franklin

Family · Munster, INNPI 1043758345

Payments from drug & device makers

$2,661in general payments, 2019–2025

Across 58 payments — averaging $45.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$698
  • Boston Scientific$407
  • Madrigal Pharmaceuticals$309
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$283
  • Optinose US, Inc.$258
  • Lilly USA, LLC$226
  • plus $480 from 5 others

What the payments were for

  • Travel & lodging$1726%
  • Food & beverage$2,48994%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,661 in reported general payments places this provider in the 80th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$1,598
Medicare patients
16
Services billed
22

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin13$23,351
OzempicSemaglutide12$21,027
MounjaroTirzepatide11$12,656
Ursodiol12$935
Atorvastatin Calcium106$914
Amlodipine Besylate102$543
Potassium Chloride20$409
Levothyroxine Sodium33$407
Lactulose14$345
Metoprolol Succinate22$345
Losartan Potassium26$243
Omeprazole28$239
Glimepiride13$233
Albuterol Sulfate HfaAlbuterol Sulfate14$223
Lisinopril44$222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$698$21,02712 claims
Lilly USA, LLCMounjaro$226$12,65611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,392 family providers in Indiana.

Other family in Munster

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →